Amanta Healthcare IPO

About the company

Incorporated in 1994, Amanta Healthcare Limited is a pharmaceutical company engaged in developing, manufacturing and marketing a diverse range of sterile liquid products, including parenteral products, packed in plastic containers using Aseptic Blow-Fill-Seal (ABFS) and Injection Stretch Blow Moulding (ISBM) technology. The company manufactures large-volume parenterals (LVPs) and small-volume parenterals (SVPs) across 6 therapeutic segments, along with medical devices. The company operates through 3 strategic business units: national sales, international sales, and product partnering with various foreign and Indian pharmaceutical companies. The company markets over 45 products under its own brands in the Indian market through a network of over 320 distributors and stockists. The international sales contributed 32.68% of total revenue in FY25 compared to 29.31% in FY24. It operates a manufacturing facility spread over 66,852 sq m in Gujarat, India. The facility includes four large-volume parenterals (LVP) manufacturing lines and three operational small-volume Parenterals (SVP) manufacturing lines. The company offers a comprehensive range of products, including fluid therapy (IV fluid), formulations, diluents, ophthalmic solutions, respiratory care and irrigation solutions in the therapeutic segment, plus products like irrigation, first-aid solutions, and eye lubricants in the medical device segment. As of 22 Aug 2025, the company has a portfolio of 47 products registered across 120 international jurisdictions. As of March 31, 2025, the company achieved overall capacity utilisation of 96%, with LVP at 91%, SVP at 99%, and SteriPort at 91% utilisation rates. Total installed capacity stands at 33.19 crore units with actual production of 31.83 crore units. Global health expenditure was US$9.8T in 2022, approximately 9.9% of world GDP. India’s current health expenditure (CHE) is only 3.3% of GDP, well below developed peers, suggesting a long runway as policy focus post-COVID sustains spending. Per-capita CHE in India is just US$273, again highlighting headroom. Health’s share in India’s private final consumption expenditure has risen steadily to 5.2% in FY24. The National Health Policy targets lifting government health outlay to 2.5% of GDP; pharma accounts for a relatively high share of CHE in India (21% in 2020), indicating structural demand for cost-effective therapies and essential hospital consumables. Amanta focuses on sterile liquids (LVPs/SVPs) across fluid therapy, diluents, ophthalmic, respiratory and irrigation, directly exposed to rising hospitalisations and procedure volumes as health spending climbs from a low base. Two-port IV fluids enjoy materially higher ceiling prices than single-port, e.g., 500 ml glucose 5% at ₹82.27 vs ₹37.98. The company sells two-port under SteriPort, allowing it to skew to higher-realisation SKUs while remaining within price controls. Now, Amanta Healthcare Ltd is launching its initial public offering (IPO), which is a complete fresh issue worth ₹126 crore. Its shares will be listed on the NSE and BSE.

Financial performance (₹ Cr)

Subscription breakup (final, times)

IPO Roadmap / Timeline

1. IPO Opens

   Completed
   01 Sept 2025

   Bidding starts for all investor categories

2. IPO Closes

   Completed
   03 Sept 2025

   Last day to place your bid

3. Basis of Allotment

   Completed
   04 Sept 2025

   Share allotment finalised

4. Refund Initiation

   Completed
   08 Sept 2025

   Refunds credited for non-allottees

5. Credit to Demat

   Completed
   08 Sept 2025

   Allotted shares credited to demat account

6. Listing on Exchange

   Completed
   09 Sept 2025

   Shares list on NSE / BSE

Post-close dates are indicative as per SEBI T+3 listing framework and may change per registrar updates.